The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of PF006730512 following multiple intravenous infusion in adult subjects with primary FSGS. You may qualify if you are a male or female ages 18 - 65, with an eGFR >45, a UPCR >1.5 g/g, also a non-Responder to a Single Treatment regimen for FSGS, considered intolerant to an Immunosuppressant and are a Non-Responder to a single treatment regimen, or considered intolerant to an Immunosuppressant and are naïve to other Immunosuppressant treatment regimens for FSGS. Must discontinue steroid treatment or tapered down to a stable prednisone dose 7.5 mg per day or other steroid equivalents to achieve a stable dose before the Lead-In Period. Participants must be willing and able to comply with scheduled visits, must comply with birth control regimen or have proof of postmenopausal status. If you are interested please contact Teresa Chacana at (205) 934-7649
You may qualify to participate in an active-control treatment study of the efficacy and safety of Sparsentan, funded by Retrophin Incorporated. Qualifying participants must be over the age of 19 years old, not on dialysis or have received a previous transplant, and have had a renal biopsy confirming diagnosis. Participants will be compensated. For more information, please contact Laura Latta via phone number 205-975-8638 or email at Alatta@uabmc.edu.